INTRODUCTION
============

> Unfortunately, most researchers in psychiatry and psychology express little interest in the mapping of autonomic regulation as a "vulnerability" dimension for various disorders and behavioral problems, although visceral features are often symptoms of the disorders they are treating.

> --[@B50]

Major depressive disorder (MDD) is associated with reduced resting-state heart rate variability (HRV; [@B34], [@B32]; [@B7]; see [@B31] for review), and these reductions are inversely associated with disorder severity ([@B34]). Heart rate and its variability (HRV) are determined by a variety of physiological factors, although the most prominent of these is the autonomic system. A high level of parasympathetic (vagal) function is both desirable and beneficial as it reflects the capacity for an individual to respond, adapt and regulate responses when required. One can only imagine the consequences of buildings in Tokyo not being sufficiently flexible to withstand an earthquake. The ability to adapt quickly to change in the environment requires flexibility. Researchers ([@B27]) have argued that a fundamental component of health is psychological flexibility and have suggested that HRV may provide the psychophysiological foundation for such flexibility ([@B17]; [@B27]). By contrast, chronic reductions in HRV are associated with psychophysiological rigidity, dysregulation of a variety of allostatic systems, and increased risk for morbidity and mortality (see [@B31] for review). The goal of the present paper is to determine whether specific subtypes of depression display more robust alterations in heart rate and commonly reported measures of HRV relative to controls.

In the resting state, the heart is under tonic inhibitory control by the vagus, yet measures of HRV are a more specific marker of vagal function than heart rate ([@B58]; [@B57]). That said, different measures of HRV provide information on different physiological control mechanisms ([@B57]). For instance, high frequency oscillations (0.15--0.4 Hz) relate to respiratory influences, while LF oscillations (0.04--0.15 Hz) reflect mechanisms relating to blood pressure control such as the baroreflex ([@B57]; see also [@B38]).

Reduced HRV was first reported in depressed patients more than two-decades ago ([@B9]), and more recently, has been shown to predict adverse cardiovascular events over a follow-up period of 3--15 years ([@B26]), highlighting the importance of continued research in this area. However, not all studies ([@B41]) -- including our own ([@B30]) -- have reported reduced HRV in depressed patients highlighting the complexity of this issue. Recent debate has focused on whether the mood and anxiety disorders, or their treatments are associated with reductions in vagal function ([@B42]; [@B8]). Increases in heart rate are usually associated with decreases in HRV, and antidepressant medications clearly adversely affect heart rate and HRV ([@B40]; [@B30]), yet uncertainty remains over whether unmedicated depressed patients display alterations in these psychophysiological markers ([@B28], [@B29]; [@B33], [@B30]; [@B42]; [@B8]).

One potential explanation for the contradictory findings is that distinct subtypes (e.g., melancholia; [@B18]; [@B44]) may display more robust alterations in heart rate and HRV, yet studies are yet to determine whether this is the case. Melancholia is characterized by an over-active stress response, a loss of responsiveness to the environment, somatic symptoms (e.g., insomnia, loss of appetite), and worse depression in the morning ([@B18]). In addition, patients with melancholia display greater cognitive impairment relative to those without such features ([@B51]). There are several reasons to expect that HRV will be reduced in depression generally, and that these effects will be greatest in those patients with melancholic depression. These include the presence of somatic symptoms, cognitive impairment, increased disorder severity, and reduced responsiveness to the environment; all symptoms that have been previously associated with HRV reductions.

Firstly, somatic depressive symptoms appear to be strongly associated with reduced HRV, at least in patients with stable coronary heart disease ([@B13]). Secondly, there is a body of evidence linking cognitive function and executive function in particular to HRV (see [@B67] for review; Kemp et al., unpublished findings). Participants with high HRV have been shown to perform better on executive function tasks relative to those with low HRV. These effects have been observed in a variety of populations including young men ([@B22]) and older women ([@B35]), while performance on cognitive tasks has been shown to improve with aerobic exercise ([@B22]; [@B2]). Thirdly, melancholic depression is generally a more severe form of depression -- although differences between melancholia and non-melancholia are more than simple variation on severity ([@B52]) -- and reductions in HRV are correlated with increasing depression severity ([@B34]). Fourthly, the capacity to adequately respond to change in the environment requires flexibility -- melancholic patients are less responsive -- and HRV may provide the psychophysiological foundation for such flexibility ([@B68]; [@B27]). Finally, it is notable that stimulation of the left vagus nerve is a promising, alternative treatment for treatment resistant depression ([@B46]), further highlighting a role for impaired vagal function in MDD.

We have reported reductions in MDD patients across time-, frequency- and non-linear domain measures of HRV ([@B32]; see also [@B7]), findings associated with a small-to-moderate effect size, replicating findings we reported in an earlier meta-analysis ([@B34]). One of our previous studies ([@B32]) further highlighted that reductions in HRV were greatest in MDD patients with comorbid generalized anxiety disorder, findings associated with a large effect size. Confirming these findings, we recently reported, in an independent Brazilian sample, that only those with generalized anxiety disorder display robust, though small, increases in heart rate and decreases in HRV after controlling for confounding variables using propensity scores ([@B30]), a novel approach that allows for more appropriate control of confounders, and a technique we employ in the present study. Here we explore the impact of two major subtypes of depression -- melancholia and non-melancholia -- relative to controls, hypothesizing that patients with melancholic depression rather than non-melancholic depression will display robust decreases in HRV, relative to healthy controls, after controlling for major confounding variables including disorder severity ([@B34]) and comorbid anxiety ([@B32]; [@B3]; [@B10]). Here we report on a variety of HRV measures to examine the which findings are robust across different measures. On the basis of parallel lines of evidence highlighting a major role for high heart rate in future morbidity and mortality ([@B16]; [@B39]; [@B1]), we also examined the impact of depression on heart rate, expecting robust increases in heart rate in melancholia.

MATERIALS AND METHODS {#s1}
=====================

PARTICIPANTS
------------

A total of 72 patients with a primary diagnosis of MDD and 94 age- and sex-matched controls were included in this study. Participants in this study were recruited from the community as part of case-control study conducted in 2006 and 2007 ([@B32]). Exclusion criteria included a history of brain injury (causing loss of consciousness for 10 min or more), neurological disorder, other serious medical condition, or substance abuse or dependence for \>1 year. All participants were medication free for at least five half-lives. Our study was approved by the University of Sydney, Sydney West Area Health Service, University of Adelaide and Flinders University human research ethics committees, and written informed consent was obtained from participants in accordance with National Health and Medical Research Council guidelines.

PROCEDURES
----------

Depressed participants were diagnosed with MDD and categorized with or without melancholic symptoms by trained and supervised research officers using the Mini International Neuropsychological Interview (MINI; [@B61]), a structured psychiatric interview based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Control participants were excluded if they self-reported a history or presence of psychiatric illness; they were also screened using the MINI. Depression severity was assessed using the 17-item structured interview guide for the Hamilton Depression Rating Scale (SIGH-D; [@B21]; [@B72]) and psychomotor disturbance was measured by the CORE assessment of psychomotor change (CORE; [@B24]). The self-report, Depression, Anxiety and Stress Scale (DASS; [@B43]) was completed by participants at the completion of the clinical interview. The DASS depression subscale is compatible with DSM-IV criteria of mood disorders, the Anxiety scale, with symptom criteria of panic disorder and PTSD, and the Stress scale, with a diagnosis of generalized anxiety disorder.

Participants were seated in a sound and light controlled room at 24°C and two 2-min electrocardiogram (ECG) recordings were collected during resting state. The ECG recording disc was positioned on the inside of the left wrist, positioned at the radial pulse, relative to a common ground and referenced to two sites: Erbs point (located two thirds distant from midline on the clavicle) and C7 (the seventh Cervical vertebra; most pronounced transverse process). Both reference sites are positioned directly above bone and serve as relatively muscle-free references. Recordings were made under these conditions as part of a standardized, psychophysiological recording protocol ([@B20]).

Data was sampled at 500 Hz, with 22-bit resolution digitization using a Compumedics Neuroscan Nuamps amplifier and SCAN software, version 4.3. ECG was analyzed using custom-developed software to perform semi-automated pre-processing to remove noise from the ECG, allowing for the identification of the R-peaks based on established methods ([@B47]). The cleaned, N-N time-series for each participant was then imported into Kubios (version 2.0, 2008, Biosignal Analysis and Medical Imaging Group, University of Kupio, Finland, MATLAB) from which measures of heart rate and HRV were calculated based on established guidelines ([@B15]).

HEART RATE MEASURES
-------------------

Heart rate and its variability during the resting-state are under tonic inhibitory control by the parasympathetic (vagal) nervous system ([@B67]). It is in this regard that we refer to resting-state heart rate and HRV as surrogate measures of vagally mediated cardiac activity, although HRV measures are more pure ([@B58]), yet complex ([@B49]), indicators of vagal activity. HRV measures comprised time-domain estimates, including the standard deviation of N--N intervals (SDNN) and the square root of the mean squared differences between successive N--N intervals (RMSSD). SDNN is a commonly reported time-domain measure reflecting all the cyclic components responsible for variability in a recording ([@B15]). RMSSD is a stable, time-domain index less affected by changes in breathing frequency ([@B48]). We also examined frequency-based estimates using the FFT method including the absolute power of high frequency (HF, 0.15--0.4 Hz) and low frequency (LF, 0.04--0.15 Hz). HF relates to respiratory influences, while LF provides information about baroreflex function ([@B19]). The standard deviation of the Poincaré plot perpendicular to the line of identity (PCSD1), a non-linear measure of HRV, was also calculated. We have previously reported that non-linear domain measures of HRV may be more sensitive to group differences ([@B34]). Heart rate displays complex non-linear dynamic behavior, rather than regular, periodic oscillation ([@B5]), and the PCSD1 is a commonly reported, non-linear measure of short-term variability mainly caused by respiratory sinus arrhythmia ([@B65]). All HRV measures were log transformed to normality.

DATA PROCESSING AND STATISTICAL ANALYSIS
----------------------------------------

All statistical analyses were performed using IBM SPSS Statistics, Version 21 with SPSS R Essentials plug-in and R statistics version 2.14.2. To avoid bias resulting from imbalance on disorder severity and comorbid anxiety -- major confounding variables when seeking to compare patients with melancholia and non-melancholia -- we conducted propensity score matching (PSM) using a custom designed plugin for IBM SPSS Statistics ([@B70]). PSM involves producing a score (on the basis of entered covariates) for each participant that relates to the probability that the subject belongs to the melancholic versus non-melancholic grouping, and then matching patients in each grouping on this propensity score. If two participants have the same propensity score, then they are equally likely to have come from the same distribution (i.e., patient grouping). Therefore, selecting patients with non-melancholia that have the same propensity scores to those with melancholia, we avoid any bias resulting from an imbalance on covariates. The PSM procedure uses logistic regression to produce the propensity score, in which patient grouping is used as the outcome variable and selected covariates, as predictors. Covariates entered into PSM analysis included age, gender, depression, anxiety and stress DASS scores, SIGH-D, and MINI anxiety disorder status (yes, no). Cases with the closest score were then matched using a simple 1:1 nearest neighbor matching routine based on a 'greedy' matching algorithm. Balance statistics and associated graphs were inspected to confirm adequacy of the match.

As PSM requires a complete dataset without missing data, we first ran multiple imputation (MI) analysis ([@B60]) in IBM SPSS Statistics to replace missing values using the automatic method. While a common approach to dealing with missing data is deleting observations with missing values, and analyzing only those participants with a complete dataset, this listwise deletion approach is problematic for at least two reasons ([@B4]; [@B71]). Firstly, it wastes data and reduces the power of analysis to determine an effect. Secondly, it may also produce biased estimates when loss of participants is systematic and not random. By contrast, MI yields estimates with good statistical properties. It uses all available data, makes less stringent assumptions about 'missingness' and pools plausible complete versions of an incomplete dataset into one analysis taking into account additional uncertainty due to missing data.

Data was missing for the following variables: depression (melancholia: 27.5%; non-melancholia: 37.5%), anxiety (melancholia: 22.5%; non-melancholia: 37.5%), and stress (melancholia: 22.5%; non-melancholia: 37.5%) from the DASS measure, MINI anxiety disorder status (yes, no; melancholia: no missing data; non-melancholia: 6.3%), and CORE total (melancholia: no missing data; non-melancholia: 3.1%) as predictors. MI procedures are appropriate for data in which up to 60% of values are missing ([@B4]). As recommended by others ([@B45]), the imputation model used for missing data contained all variables to be subsequently analyzed including outcome variables (melancholic status in PSM, and heart rate and its variability in final analysis), variables to predict the missing data, and those variables to be imputed. Variables entered into MI analysis included: participant grouping, heart rate and HRV, depression, anxiety and stress from the DASS questionnaire, age, gender, SIGH-D, MINI anxiety disorder status and CORE total score.

Multiple imputation analysis produced 20 datasets relating to 72 MDD patients and PSM analysis was run on each of these datasets to obtain patients matched on propensity scores. The data for controls were then merged into each of the 20 datasets after which analyses were conducted on each dataset to examine group differences (MEL vs. NMEL vs. CTRL) on heart rate and HRV. As recommended previously ([@B25]), analysis of variance (ANOVA) analysis was carried out as a regression analysis using effect coding ([@B14]; [@B71]) so that results could then be combined according to Rubin's rules ([@B71]). This approach has the advantage of averaging over the results from different groupings determined using PSM on the multiply imputed datasets ([@B25]). Guidelines and software for carrying out these procedures and combining results for pooled estimates and statistics are available here: <http://www.socialsciences.leiden.edu/educationandchildstudies/childandfamilystudies/organisation/staffcfs/van-ginkel.html>. One-tailed *t*-tests are reported given specific directional hypotheses. Effect size measures (Cohen's *d*) were also determined and Cohen's guidelines ([@B11]) for interpreting Cohen's *d*'s (small, *d* = 0.2; medium, *d* = 0.5; large, *d* = 0.8) were followed. Cohen's *d* statistics were calculated using an online calculator available here: [http://www.uccs.edu/\$\\sim \$lbecker/](http://www.uccs.edu/$\sim$lbecker/)

RESULTS
=======

PARTICIPANT CHARACTERISTICS
---------------------------

Participant characteristics are reported in **Table [1](#T1){ref-type="table"}**. No age or gender differences were observed, however, all groups differed on depression, anxiety and stress scales (Tukey's HSD *p* \< 0.05), highlighting the need for PSM of patients in melancholia and non-melancholia patient groupings.

###### 

Participant characteristics: mean (*M*) ± standard error (SD).^**1**^

           CTL (*M* ± SE)   NMEL (*M* ± SE)   MEL (*M* ± SE)   *p*-value^2^
  -------- ---------------- ----------------- ---------------- --------------
  Age      35.69 ± 1.16     34.98 ± 1.56      37.28 ± 2.07     0.657
  Gender   52F/42M          17F/15M           25F/15M          0.675
  SIGH-D   n/a              18.78 ± 0.68      21.50 ± 0.69     0.007
  DASS-D   2.13 ± 0.25      21.70 ± 2.04      31.66 ± 1.39     \<0.001^3^
  DASS-A   1.19 ± 0.19      9.30 ± 1.79       15.23 ± 2.15     \<0.001^3^
  DASS-S   4.54 ± 0.47      19.00 ± 1.83      23.93 ± 1.88     \<0.001^3^
  CORE     n/a              3.45 ± 0.53       7.18 ± 0.86      \<0.001^3^

1

M

± SE values based on original -- not imputed data -- data before propensity score matching of patient groupings;

2

p

-value refers to that for omnibus ANOVA, or for SIGH-D and CORE, an independent-samples

t

-test;

3

post hoc

tests revealed that all groups differ from each other, Tukey's HSD

p

\< 0.05

.

HEART RATE AND ITS VARIABILITY
------------------------------

After application of PSM and pooling results according to Rubin's rules, groups differed significantly on heart rate \[*F*(2,108.25) = 3.664, *p* = 0.029\], RMSSD \[*F*(2,107.86) = 3.21, *p* = 0.044\], HF (at trend levels) \[*F*(2,102.76) = 2.966, *p* = 0.056\], and PCSD1 \[*F*(2,107.87) = 3.199, *p* = 0.045; **Figure [1](#F1){ref-type="fig"}**\]. No significant differences on the combined overall test were observed for SDNN or LF. As hypothesized, heart rate was increased (by 7.85 beats per minute, BPM) in patients with melancholia -- but not in those with non-melancholia -- relative to controls (*p* = 0.004, one-tailed, *d* = 0.58). Also as hypothesized, HRV was decreased in patients with melancholia -- but not in those with non-melancholia -- relative to controls. More specifically, RMSSD (*p* = 0.01, one-tailed, *d* = 0.56), HF (*p* = 0.014, one-tailed, *d* = 0.57) and PCSD1 (*p* = 0.01, one-tailed, *d* = 0.56) were all decreased in patients with melancholia, relative to controls. No significant differences were observed between non-melancholia and controls. While patients with melancholia had higher heart rate than those with non-melancholia (by 6.75 BPM; *p* = 0.046, one-tailed, *d* = 0.20), no significant differences on measures of HRV were observed between melancholia and non-melancholia.

![**Means and standard error for participant groupings (controls, non-melancholia, melancholia) across each of the dependent measures after controlling for age, gender, disorder severity, and comorbid anxiety disorders with propensity score matching**.](fpsyg-05-01387-g001){#F1}

DISCUSSION
==========

The current study examined the impact of melancholia and non-melancholia on resting-state heart rate and HRV relative to controls, revealing robust alterations in patients with melancholia, but not in those with non-melancholia. These findings were associated with a moderate effect size across multiple measures (Cohens *d*'s = 0.56--0.58), providing strong evidence for an impact of melancholia on vagally mediated, cardiac function. We also observed patients with melancholia to display a higher heart rate, relative to those with non-melancholia. We and others have demonstrated that HRV is inversely associated with disorder severity ([@B34]) and that antidepressant medications -- particularly tricyclic antidepressants and the serotonin and noradrenaline reuptake inhibitors often used in more severe depressions -- have adverse effects on heart rate and HRV after controlling for disorder severity ([@B40]; [@B30]). Together, these findings suggest that alterations in melancholic patients with severe depression treated with antidepressant medications would be stronger than those effects reported here, as our patients were all unmedicated.

Here we show that resting-state heart rate is increased -- by almost eight beats per minute -- and HRV, decreased in patients with melancholia relative to healthy controls, findings associated with a moderate effect size. An increased resting-state heart rate may reflect vagal withdrawal without necessarily, an increase in sympathetic nervous system activity ([@B50]; [@B30]). This metabolically conservative response is usually observed during environmental challenge. We have suggested ([@B30]) that this psychophysiological state may mirror the autonomic dysregulation observed in psychiatric illness during the resting-state, and the present study highlights that this may be the case for those with melancholia in particular. As noted above however, measures of HRV are more pure indicators of vagal activity ([@B58]) than heart rate, which also includes sympathetic input. Differences in heart rate were also observed between those with melancholia and non-melancholia, with those with melancholia displaying a higher heart rate, a difference of 6.75 BPM, a finding associated with a small effect size (Cohens *d* = 0.20). No differences however, were observed on measures of HRV. We suggest that this finding may reflect differences in a non-vagal (perhaps sympathetic) component of cardiac function. It is possible therefore that while vagal function distinguishes between patients and controls, non-vagal components of heart rate may further distinguish between disorder subtypes.

Critically, studies have reported strong evidence for a continuous increase in risk for cardiovascular and all-cause mortality in men and women with a resting heart rate above 60 beats/min, regardless of whether individuals have a history of cardiovascular disease ([@B16]; see also [@B12]; [@B59]). Here we observed patients with melancholia to display a higher resting, heart rate (78.48 BPM) relative to controls (70.63 BPM) and those with non-melancholia (71.73 BPM). Other studies ([@B39]; [@B1]) have reported a relationship between high heart rate and suicide. In fact, 10 additional beats per minute has been shown to increase risk of suicide by 24 to 37% over a 9 year follow-up period in adjusted models ([@B39]). Another study on more than 1-million, 18-year-old participants with no prior mental illness ([@B1]) reported that poor performance on cardiovascular fitness and cognitive tests was associated with a fivefold increased risk of suicide attempt or death over a 5- to 42-year follow-up period.

In addition to increases in heart rate, we also observed decreases in all measures of HRV except for SDNN and LF in patients with melancholia relative to controls. While SDNN reflects the 'ebb and flow' of a variety of factors including respiration, blood pressure control mechanisms, thermoregulation and kidney functioning, RMSSD is a more specific index of vagal function that correlates highly with the high-frequency component of HRV ([@B36]). Recent thinking also indicates that the low-frequency component of HRV reflects blood pressure control mechanisms such as the baroreflex ([@B19]; [@B57]). It is possible therefore that SDNN from short-term recordings is less sensitive than that extracted from 24-h long recordings, and that blood pressure control mechanisms are less involved in the differences observed here between patients with melancholia and controls.

A recent meta-analysis ([@B26]) reported that HRV can predict the first cardiovascular event in individuals without known cardiovascular disease over a period of 3.5 to 15 years. Cardiovascular endpoints included hospitalization for angina pectoris, myocardial infarction, congestive heart failure, arterial peripheral vascular disease, coronary revascularization, stroke and cardiovascular death. This meta-analysis ([@B26]) was based on eight studies with a total of 21,988 participants without known cardiovascular disease at baseline and reported pooled relative risks for a first cardiovascular event ranging from 1.35, 1.45, and 1.32 for SDNN, low-frequency or high-frequency HRV measures respectively. The authors proposed two possible mechanisms for their findings including vagal dysregulation activating inflammatory processes culminating in cardiovascular events. The other suggested mechanism was that individuals with low HRV already suffer from subclinical or silent CVD, highlighting that reduced HRV may be both a cause and consequence of ill health. Importantly, participants in the present study were free from serious medical conditions that may have otherwise impacted on the findings reported here.

It is important to note that our findings were obtained after accounting for a variety of confounding variables including severity of depression, anxiety and stress, and number of comorbid anxiety disorders. No significant differences were observed between patients with non-melancholia and controls, suggesting that heterogeneity in patient samples may underpin some of the past null findings that have been reported in the literature. Strengths of the present study include a medication free and physically healthy sample, and application of PSM to control for a variety of confounding variables across patient groupings. It is also important to acknowledge some limitations of our study. There are potential confounding factors that we did not control for here including physical activity ([@B56]; [@B63]), smoking status ([@B62]; [@B23]), alcohol use ([@B53],[@B54]), body mass index ([@B6]; [@B37]), and biomarkers including fasting glucose ([@B64]) and cholesterol ([@B6]; [@B66]), all of which may impact on heart rate parameters. We refer interested readers to a recent review of the various issues that researchers should consider when collecting measures of HRV ([@B55]). Regardless, we note here that many of these factors known to impact on heart rate parameters are also observed in patients with mood disorders, highlighting the importance of cardiovascular risk reduction strategies in such patients, and on the basis of the present study, those with melancholic symptoms in particular.

In conclusion, we report here that patients with melancholia -- but not non-melancholia -- display robust reductions in resting-state HRV relative to controls. This finding was observed even when applying PSM, a relatively novel technique to ensure that patient groupings did not differ on important confounds including age, gender, severity of depression, anxiety and stress, and comorbid anxiety disorders. Reduced vagal tone has important functional significance (e.g., impaired psychological flexibility; [@B68]; [@B27]), and over the longer-term may lead to significant morbidity and mortality from a host of conditions ([@B69]; [@B31]). Our study therefore, has important implications for the health and wellbeing of patients with melancholic depression. Future studies are needed to further examine what particular behavioral features are most associated with the alterations in heart rate and HRV in patients with melancholia.
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